Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 5/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.31 |
| ▸ | XPO1 | O14980 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20088531 | 0.81 | HAVCR2 (0.41) | HAVCR2 | |
| SCHEMBL20094291 | 0.77 | TP53 (0.36) | XPO1HTT | |
| SCHEMBL20094632 | 0.74 | HTT (0.33) | HTT | |
| SCHEMBL20094364 | 0.73 | ADORA2A (0.39) | HAVCR2 | |
| SCHEMBL20094349 | 0.73 | HRH4 (0.35) | XPO1 | |
| SCHEMBL20094270 | 0.71 | PDE10A (0.32) | XPO1 | |
| SCHEMBL20094617 | 0.68 | PDE2A (0.36) | — | |
| SCHEMBL20088561 | 0.67 | PDE10A (0.38) | HAVCR2HTT | |
| SCHEMBL20089005 | 0.67 | P2RX7 (0.36) | HAVCR2XPO1 | |
| SCHEMBL20088555 | 0.66 | KDM4E (0.36) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109963851-B | Fused bicyclic pyridine compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3532477-B1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-26 | — | — | EP | disclosed |
| WO-2018080917-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111933-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111933-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN3A, GRM1 | HAVCR2 3281/4885GPR139 122/4885XPO1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.